The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus NSAI in patients with HR+, HER2- advanced breast cancer, the clinical impacts of the availability of abemaciclib, and the results of the interim overall survival analysis.
The abstract entitled ‘MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)‘ Abstract LBA5, was presented at European Society for Medical Oncology (ESMO) 2022.
- What did the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+, HER2- advanced breast cancer (ABC)? (0:13)
- What has been the clinical impact of the availability of abemaciclib? (1:27)
- What were the results of the interim overall survival analysis? (2:27)
- Why do you think these findings failed to achieve statistical significance? (3:31)
- What further study is needed to optimise the clinical use of abemaciclib in ABC? (3:59)
Disclosures: Matthew P. Goetz serves as a paid consultant and receives grants for research funding paid to his institution from Eli Lilly and Company in support of the MONARCH 3 trial; reports personal fees from Genomic Health; consulting fees to his institution from AstraZeneca, Biovica, Pfizer, Novartis, Sermonix, Context Pharm, Eagle Pharmaceuticals; grants to his institution from Pfizer, Sermonix; honoraria to his institution for serving on the advisory board for ARC Therapeutics, Blueprint Medicines, Biotheranostics, and Sanofi Genzyme; personal fees from Research to Practice, Clinical Education Alliance, Medscape, MJH Life Sciences for CME presentations; and personal fees from Total Health Conferencing serving as a panelist, outside the submitted work.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!